🧬 RETATRUTIDE PHASE 3: TRIUMPH-1
TRIUMPH-1 moved retatrutide research into a large Phase 3 obesity trial.
In reported results, participants receiving the 12 mg dose had an average 28.3% reduction in body weight at 80 weeks.
That’s a trial average — not a promise of what any individual would experience.
The study gives researchers a much larger human dataset than the earlier Phase 2 work.
Retatrutide remains investigational and is not FDA-approved as of this post.
Big number, but context still matters. 🧬